oral PARP1-DNA selective trapper

1 mpk QD in PDX model, phase I/II, cancer

from literature starting point

Journal of Medicinal Chemistry



The AstraZeneca PARP1-DNA trapper, AZD5305, is a phase I candidate (NCT04644068) for cancer that is selective for PARP1 over PARP2 (>500x). Their study began by profiling the existing clinical and late-stage…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: